Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials
Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials
复制标题
DOI：
10.1038/jhh.2010.85
复制
发表时间：
2011-07-01
影响因子：
2.7
通讯作者：
Borghi, C.
中科院分区：
文献类型：
--
作者：
Cicero, A. F. G.;Gerocarni, B.;Borghi, C.
口服乳三肽缬氨酸-脯氨酸-脯氨酸（VPP）和异亮氨酸-脯氨酸-脯氨酸（IPP）作为营养品或功能性食品被认为是通过抑制血管紧张素转化酶来改善血压（BP）控制。然而，来自临床试验的数据得出了相互矛盾的结论。对假定为营养保健品或功能性食品的乳三肽的降压作用进行安慰剂对照临床试验的荟萃分析。在PubMed中使用定义的检索策略识别的试验被纳入荟萃分析，并使用随机效应模型估计其合并效应，对方差的倒数进行加权。进行异质性、发表偏倚、亚组和荟萃回归分析。共确定了18项试验，并明确报告了其临床数据。肽的合并效应是收缩压（SBP）降低-3.73 mm Hg（95% CI：-6.70，-1.76），舒张压（DBP）降低1.97 mm Hg（95% CI：-3.85，-0.64）。这种效果在亚洲患者中更为明显（SBP = -6.93 mmHg（95% CI：-10.95，-2.94）; DBP = -3.98 mmHg（95% CI：-5.38，-2.44））（收缩压= -1.17 mmHg（95%CI：-2.82，0.72）;舒张压= -0.52 mmHg（95%CI：-1.39，0.13）），并且显然与年龄、基线BP值、假定的乳三肽剂量或治疗时间长度无关。假设VPP和IPP乳三肽是功能性食品，可显著降低SBP，特别是在亚洲受试者中。这一发现在其他种族中的相关性或与不同饮食模式的相关性应进一步研究。Journal of Human Hypertension（2011）25，425-436; doi：10.1038/jhh.2010.85; 2010年9月2日在线发表
The oral assumption of lactotripeptides Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP) as nutraceuticals or functional foods is supposed to improve blood pressure (BP) control by angiotensin-converting enzyme-inhibition. However, data derived from clinical trials have reached conflicting conclusions. To perform a meta-analysis of placebo-controlled clinical trials evaluating the anti-hypertensive effect of lactotripeptides assumed as nutraceuticals or functional foods. Trials identified using a defined search strategy in PubMed were included in the meta-analysis, and their pooled effect was estimated with a random effects model, weighting for the inverse of the variance. Heterogeneity, publication bias, subgroup and meta-regression analyses were performed. A total of 18 trials have been identified, the clinical data of which have been clearly reported. Pooled effect of peptides was a reduction of -3.73 mm Hg (95% CI: -6.70, -1.76) for systolic blood pressure (SBP) and 1.97 mm Hg (95% CI: -3.85, -0.64) for diastolic blood pressure (DBP). The effect was more evident in Asian patients (SBP = -6.93 mm Hg (95% CI: -10.95, -2.94); DBP = -3.98 mm Hg (95% CI: -5.38, -2.44)) than in Caucasian ones (SBP = -1.17 mm Hg (95% CI: -2.82, 0.72); DBP = -0.52 mm Hg (95% CI: -1.39, 0.13)), and apparently not related to age, baseline BP values, dose of lactotripeptides assumed or length of the treatment. VPP and IPP lactotripeptides assumed as functional foods may significantly reduce SBP particularly in Asian subjects. The relevance of this findings in other ethnicities or associated with different dietary pattern should to be further investigated. Journal of Human Hypertension (2011) 25, 425-436; doi:10.1038/jhh.2010.85; published online 2 September 2010